Key Market Indicator:
F&G: 23
25.437,00 NASDAQ · 47.695,00 DOW · 6.818,20 S&P · 4.222,77 Gold · 62,24 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
FR0000120578
Filter zurücksetzen
© Globe Newswire
15.05.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares - April 2025
Article
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares - March 2025
Article
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.04.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Annual General Meeting of April 30, 2025
Article
News Preview
Annual General Meeting of April 30, 2025...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
30.04.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Article
News Preview
Sanofi and CD&R close Opella transaction, create global consumer healthcare leader...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
29.04.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
Article
News Preview
When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.04.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
Article
News Preview
When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.04.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Article
News Preview
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.04.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse - Sanofi inaugure en France sa nouvelle unité d’excellence R&D Vaccins
Article
News Preview
Sanofi inaugure en France sa nouvelle unité d’excellence R&D Vaccins...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.04.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Article
News Preview
Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.04.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Article
News Preview
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.04.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares - February 2025
Article
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.04.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Article
News Preview
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
28.03.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Article
News Preview
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.03.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Article
News Preview
 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.03.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
Article
News Preview
Chlamydia vaccine candidate granted fast track designation by the US FDA...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.03.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
Article
News Preview
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.03.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Availability of the Q1 2025 Aide mémoire
Article
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Article
News Preview
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.03.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Article
News Preview
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.03.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press release: Sanofi successfully prices EUR 1.5 billion of bond issue
Article
News Preview
Sanofi successfully prices EUR 1.5 billion of bond issue ...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Article
News Preview
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma ...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse : Sanofi lance la tournée de Zeus, le cheval métallique de la cérémonie d’ouverture
Article
News Preview
Sanofi lance la tournée de Zeus, le cheval métallique de la cérémonie d’ouverture...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.02.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
Article
News Preview
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.02.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi and CD&R sign Opella share purchase agreement
Article
News Preview
Sanofi and CD&R sign Opella share purchase agreement...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.02.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Article
News Preview
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.02.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Article
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.02.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Execution of a share buyback agreement for up to €2 billion
Article
News Preview
Execution of a share buyback agreement for up to €2 billion...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.01.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Article
News Preview
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant ...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares - December 2024
Article
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
Article
News Preview
Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.01.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Opella reaches study milestone for Cialis
Article
News Preview
 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.01.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares – November 2024
Article
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)  ...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Article
News Preview
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
Article
News Preview
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.12.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
Article
News Preview
Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
Article
News Preview
Jean-Paul Kress to join Sanofi's Board of Directors...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.12.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Article
News Preview
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
Article
News Preview
Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
Article
News Preview
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.12.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Article
News Preview
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Article
News Preview
Availability of the revised financial statements for Sanofi excluding Opella...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares - October 2024
Article
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.11.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse - Sanofi renforce la bioproduction d’anticorps en France avec un investissement de plus de 40 millions d’euros sur son site de Lyon Gerland
Article
News Preview
 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.11.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Article
News Preview
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse - Aadil BEZZA rejoint Sanofi comme Directeur des Ressources Humaines France
Article
News Preview
Aadil BEZZA rejoint Sanofi comme Directeur des Ressources Humaines France...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse : Sanofi, CEMKA, Lifen et la SFGM-TC s'unissent pour apporter une meilleure compréhension du parcours de soins des patients français souffrant de la maladie du greffon contre l’hôte chronique
Article
News Preview
Sanofi, CEMKA, Lifen et la SFGM-TC s'unissent pour apporter une meilleure compréhension du parcours de soins des patients français souffrant de la maladie du greffon contre l’hôte chronique...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Article
News Preview
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse - Sanofi obtient l’Autorisation de Mise sur le Marché d’Efluelda, son vaccin trivalent haute dose, pour la prochaine saison grippe 2025/2026
Article
News Preview
 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares - September 2024
Article
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.10.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse : Sanofi en discussions pour céder une participation majoritaire dans Opella
Article
News Preview
Sanofi en discussions pour céder une participation majoritaire dans Opella...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.10.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi in discussions to sell a controlling stake in Opella
Article
News Preview
Sanofi in discussions to sell a controlling stake in Opella...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
Article
News Preview
 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.09.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Article
News Preview
 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.09.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Article
News Preview
Dupixent approved in China as the first-ever biologic medicine for patients with COPD...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Availability of the Q3 2024 Aide mémoire
Article
News Preview
Availability of the Q3 2024 Aide mémoire...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse France : Sanofi devient membre fondateur de la Fondation de l’Université Paris-Saclay et apporte son soutien financier dans le cadre d’une convention de mécénat
Article
News Preview
Sanofi devient membre fondateur de la Fondation de l’Université Paris-Saclay et apporte son soutien financier dans le cadre d’une convention de mécénat...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.09.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Article
News Preview
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant        ...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.09.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Article
News Preview
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.09.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Article
News Preview
Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2024
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares - August 2024
Article
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 01.12.2025, Calendar Week 49, 335th day of the year, 30 days remaining until EoY.